Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06600178 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study Targeting Myocardial Perfusion and Symptom Relief in Women With SGLT2 Inhibitors (STRONG)

Study acronym: STRONG
StatusRecruiting
PhasePhase 1
Started2025-07-15
View on ClinicalTrials.gov ↗
The goal of this clinical trial is to that Sodium-glucose cotransporter 2 inhibitors treatment will improve Coronary Microvascular Disease with anginal symptoms associated with non-obstructive coronary disease in women. The main questions it aims to answer are: Aim 1: Test the hypothesis that Sodium-glucose cotransporter 2 inhibitors treatment improves coronary microvascular disease in women with no evidence of epicardial obstructive coronary artery disease. Aim 2: Test the hypothesis that Sodium-glucose cotransporter 2 inhibitors treatment improves angina symptoms and other quality of life measurements associated with the improvement of CFR. AIM 3: Identify the effect of Sodium-glucose cotransporter 2 inhibition on inflammation pathways and markers of systemic Research will compare Brezavvy to placebo Participants will: * Take study drug or placebo for 12 weeks * Stress Cardiac magnetic resonance imaging * 12 lead electrocardiograms * Complete questionnaires

Amendment history 3 changes detected by DataLookout

2026-09-10
Primary completion pushed: 2026-03 → 2027-10-31
2026-09-10
Completion pushed: 2026-10 → 2029-06-29
2026-09-10
Interventions modified
Trial Details
NCT Number NCT06600178
Lead Sponsor University of Virginia
Conditions Angina Patients With Non-obstructive Coronary Artery Disease, Coronary Microvascular Disease, Coronary Microvascular Dysfunction (CMD)
Enrollment 150 participants
Start Date 2025-07-15
Primary Completion 2027-10-31 (estimated)
Study Completion 2029-06-29 (estimated)
Updated on ClinicalTrials.gov 2026-09-09